中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (10): 829-832.doi: 10.19401/j.cnki.1007-3639.2017.10.011

• 综述 • 上一篇    下一篇

转移性肾癌中免疫治疗的研究进展

曹达龙 综述,叶定伟 审校   

  1. 复旦大学附属肿瘤医院泌尿外科,复旦大学上海医学院肿瘤学系,上海 200032
  • 出版日期:2017-10-30 发布日期:2017-12-05
  • 通信作者: 叶定伟 E-mail:dwyeli@163.com
  • 基金资助:
    国家自然科学基金资助项目(81302213)。

Advances in immunotherapy for metastatic renal cancer

CAO Dalong, YE Dingwei   

  1. Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
  • Published:2017-10-30 Online:2017-12-05
  • Contact: YE Dingwei E-mail: dwyeli@163.com

摘要: 肾癌是男性泌尿生殖系统中常见的恶性肿瘤。然而,约25%的肾癌在确诊时已是晚期,另有1/3的局限性肾癌在手术后出现复发转移。近年来,免疫治疗在转移性肾癌治疗中已取得重大进展,尤其是一些免疫治疗药物(如免疫检查点抑制剂、肿瘤疫苗等)已被证实能改善晚期肾癌患者的预后。该研究将综述免疫治疗在晚期转移性肾癌中的应用和研究进展。

关键词: 转移性肾癌, 免疫治疗, 免疫检查点抑制剂, 肿瘤疫苗

Abstract: Renal cancer is one of the most common genitourinary carcers. However, 25% patients present with locally invasive or metastatic renal cancer at the time of diagnosis, and one third of patients who received  esection of localized disease will have a recurrence or progression. Recently, immunotherapy for renal cancer has made significant progress. Especially, some immunotherapeutic agents (such as immune checkpoint inhibitor, tumor vaccine) have been proved to improve the prognosis of patients with metastatic renal cancer. In this review, the effects of immunotherapeutic agents in the treatment of renal cancer were summarized.

Key words: Metastatic renal cancer, Immunotherapy, Immune checkpoint inhibitor, Tumor vaccine